Hacker Newsnew | past | comments | ask | show | jobs | submitlogin

It turns out that microscopic impurities within specifications can still be a problem if they're potent enough.

Same would've happened state-side if the production was still there too.



So you’re saying it wasn’t just the generics, but the name-brand drugs, too?


For ranitidine, yes.




Guidelines | FAQ | Lists | API | Security | Legal | Apply to YC | Contact

Search: